Newsday (New York) (12.08.05) - Monday, December 12, 2005
Kathleen Kerr

"The vaccine against human papillomavirus will markedly decrease the incidence of cervical cancer," said Dr. Juan C. Felix, chairperson of National Cervical Cancer Coalition's medical advisory board. Gardasil, he said, should be on the government's recommended list of vaccines because that would make poor, uninsured women eligible to receive it free. Cervical cancer kills mostly women who cannot afford screening, he added.

But some conservative Christian groups, while welcoming the vaccine's protective effect, worry that it could inadvertently promote promiscuity, and they oppose making the vaccine mandatory. The Family Research Council's director for life and women's issues, Pia de Soleni, hailed Gardasil as a "great advance" but added, "the issue for us is [parental] consent."

Asked if Merck is lobbying government officials to advise that pre-pubescent children receive Gardasil, Kelly Dougherty, a company spokesperson, replied: "It's not up to Merck to make that recommendation." However, Merck acknowledges it has discussed Gardasil with regulatory agencies, faith-based and women's groups.

If Gardasil becomes FDA-approved, the expert 15-member Advisory Committee on Immunizations Practices would then advise CDC whether it should be placed on a schedule of recommended vaccines. Ultimately, individual states would decide whether to make vaccination mandatory and to whom Gardasil should be administered. Vaccination would take three shots over six months.

GlaxoSmithKline is seeking European approval of its own HPV vaccine next year but would not say when it will apply for US approval.
051212
AD052495

Copyright © 2005 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.